Patient Assistance Programs. PTC shall be solely responsible for the conduct of any expanded access, early access, free-of-charge and other programs with respect to the Products in the PTC Territory. PTC shall be responsible for ensuring that such programs shall be consistent with any global safety monitoring standards provided by Akcea to the JSC and approved by the JSC for use in the PTC Territory.
Patient Assistance Programs. Sellers shall be authorized to continue its patient assistance programs for the Product(s) for all patients enrolled and active in such programs as of the Transition Date. Purchasers hereby authorize Sellers to reserve and utilize Product(s) and to pay claims for eligible patients for a minimum of one hundred twenty (120) days following the Transition Date, after which time, patients will be removed from such patient assistance programs. Sellers shall be authorized to use Product(s) labeled with Purchasers NDC number for its patient assistance programs as necessary. Sellers shall be responsible for all costs associated with such programs, and for ensuring that such programs comply with applicable laws. Any reasonable, documented costs incurred by Purchasers, at Sellers’ request, in connection with Seller’s patient assistance programs shall be reimbursed by Sellers.
Patient Assistance Programs. The PBM agrees to have programs in place to counter the use of manufacturer's coupons/patient assistance programs that promote the dispensing of higher cost brand name drugs when a lower cost generic or alternative is available. Describe the PBMs strategy to combat the use of manufacturer's coupons. The PBM will administer a variable copayment plan design to leverage available specialty drug manufacturer patient assistance programs. The PBM’s variable copayment plan design, if selected, will be in place for the life of the contract. The Board reserves the exclusive right to amend, reduce, or eliminate any part of the Plan or change any benefits at any time. To the extent that such amendment, reduction, elimination, or change materially affects the services provided by the PBM under this Contract, the Board shall notify the PBM of such change via a letter of authorization in a timely manner and in advance of such change. In case of conflict between this Contract and the Plan Document, the Plan Document will prevail. The Board or its designee shall provide educational material to all participants explaining conditions of coverage, cost sharing, benefit design, and financial incentives encouraging compliance with the Plan’s Pharmacy Benefit Management program. The Board shall have final authority on any appeal, application, and interpretation of the Plan’s benefits or eligibility policies. The Board will not disseminate, sell, or license any proprietary information belonging to the PBM to others without the PBM’s prior written approval, unless the information is subject to the Public Records Law of the State or is required to be released by law. The effective date of this Contract will be January 1, 2021. This Contract’s term will be for four (4) years with an option to renew for one (1) year at the Board’s discretion. By March 1, 2024, the Board will notify the PBM, in writing, of the Board’s intent as to renewal of the Contract for one (1) additional year. This Contract may be terminated by either party, with or without cause, upon at least ninety (90) days prior written notice of intent to terminate. All records and information provided by the Board or through its third party contractors to the PBM are the sole property of the Board and shall be returned to the Board within thirty (30) days of the termination date of this Contract. The PBM shall be entitled to retain and utilize data that have been captured, computed, or stored in the PBM’s databases to th...
Patient Assistance Programs. Meda shall (i) inform its program administrator, physicians and patients receiving assistance for the Product under its patient assistance program of the discontinuance of coverage for the Product under the Meda patient assistance program (and the date thereof) and shall bear any costs associated with the termination of such program, and (ii) advise physicians and such patients that they will need to apply to Valeant’s patient assistance program to receive continuing assistance for the Product. The Parties shall cooperate in good faith with respect to the transition of patient assistance program patients.
Patient Assistance Programs. (i) Corcept may contract with or sponsor foundations or organizations (“Organizations”) that offer eligibility services for free Products to Patients who have no insurance coverage or financial means to cover all or part of the full cost of the Product (the “Patient Assistance Program”). Optime shall [****]. Upon Optime’s receipt of a (A) [****] and (B) [****].
(ii) Corcept may contract with such Organization or another foundation or organization (“Co-Pay Organization”) to assist Patients who cannot afford Products to obtain financial assistance for out-of-pocket expenses from the Co-Pay Foundations “Co-Pay Assistance Program”). Optime shall [****]. Upon Optime’s receipt of a (A) [****] and (B) [****] and the [****] from the [****]. Nothing in this Section 3.8(g)(ii) shall [****].
Patient Assistance Programs. During the Term, GSK will use Commercially Reasonable Efforts to continue to support the Patient Assistance Programs by (a) overseeing Accredo's and TheraCom's enrollment of eligible Patient Assistance Program recipients, (b) providing sufficient inventories of Product to Accredo and TheraCom for distribution under the Patient Assistance Program, (c) providing Myogen with monthly reports, which reports will set forth the number of patients receiving Product under the Patient Assistance Program and the amount of Product shipped to Customers pursuant to the Patient Assistance Program, (d) issuing a credit to Myogen for any amounts paid by Myogen to GSK for Product distributed under the Patient Assistance Program, and (e) providing such additional information as reasonably requested by Myogen regarding the Patient Assistance Program.
Patient Assistance Programs. The MHLA Formulary also shall identify the pharmaceuticals for which pharmaceutical manufacturer Patient Assistance Programs (PAPs) are available for MHLA patients. Patient assistance program information may also be provided for non-formulary prior authorization approvals. During Pharmacy Phase One, Contractor shall submit, on behalf of all of its Participants, applications for any applicable PAPs. During Pharmacy Phase Two, Contractor shall cooperate with any Department efforts to submit PAP applications on a Participant’s behalf.
Patient Assistance Programs. From and after the date hereof, Buyer will have sole discretion over any patient assistance program related to the Business Product, including any decision to maintain or terminate any patient assistance program operated by Seller for the Business Product (“Seller PAPs”). If Buyer decides to terminate any Seller PAP, then Buyer and Seller shall reasonably agree in good faith on a joint communication to patients regarding the wind-down and termination of that Seller PAP. If Buyer decides to maintain any Seller PAP, then Seller shall continue to operate such Seller PAP in accordance with the terms of this Agreement.
Patient Assistance Programs. GSK shall be authorized to continue its patient assistance programs for the Product for all patients enrolled and active in such programs as of the Transition Period End Date. XenoPort hereby authorizes GSK to reserve and utilize Product and to pay claims for eligible patients for a minimum of [… * …] following the Transition Period End Date and up to [… * …] following the Transition Period End Date, after which time, patients will be removed from such patient assistance programs. GSK shall be responsible for all costs associated with such programs, and for ensuring that such programs comply with Applicable Laws. Any reasonable, documented costs incurred by XenoPort, at GSK’s request, in connection with GSK’s patient assistance programs shall be reimbursed by GSK.
Patient Assistance Programs. OTIP may require a Covered Person to apply to and participate in any Patient Assistance Program available to a Covered Person and to which the Covered Person is eligible. OTIP reserves the right to reduce the amount of a covered expense by the amount of financial assistance the Covered Person is entitled to receive under a Patient Assistance Program. For a Covered Person 65 years of age and older, Reimbursement of charges for the following expenses which are no longer eligible under a Government Plan as a result of amendments to The Ontario Drug Benefit Act, made by The Savings and Restructuring Act, will be eligible: • The portion of the charges incurred to satisfy the $100 deductible under ODB. • Once the yearly $100 deductible under ODB has been satisfied, no further eligible ODB costs will be eligible for that year.
